Introduction {#sec1-1}
============

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have become the standard of care in the management of EGFR mutant lung cancers. Compared to chemotherapeutic agents, EGFR-TKIs have proven their superiority in terms of survival and toxicity profile when treating nonsmall cell lung cancer (NSCLC) patients positive for EGFR mutation.\[[@ref1][@ref2][@ref3][@ref4]\]

With the exception of leptomeningeal metastasis where erlotinib has shown better response than gefitinib, both of these TKIs are equally efficient when treating EGFR mutant NSCLC.\[[@ref5][@ref6]\] Hence, safer toxicity profile becomes one of the most important factors when choosing these TKIs. In this study, we compared the different toxicity profiles of erlotinib and gefitinib among Indian population.

Materials and Methods {#sec1-2}
=====================

Eighty-five patients of South Indian origin were screened for EGFR mutation, at Cancer Institute, Chennai, India. EGFR mutation test was performed by scorpion probe-based amplified refractory mutation system-reverse transcription-polymerase chain reaction. Patients were started on either erlotinib 150 mg or gefitinib 250 mg in the first-line setting based on physician discretion. Patients were followed up for every month till disease progression. Detailed history and physical examination with special emphasis on drug toxicity was performed at every visit. Toxicity of TKIs was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v 4.0.\[[@ref7]\]

Results {#sec1-3}
=======

Of the 85 patients tested for EGFR mutation, 34 (40%) patients were positive for the same. Twenty-three patients were started on gefitinib and 11 patients were started on erlotinib. Demographic profile of patients started on TKIs is shown in [Table 1](#T1){ref-type="table"}.

###### 

Demograpphic profile of patients on TKI\'s therapy
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Skin toxicity was the major side effect of TKIs. Nine of the 11 patients treated with erlotinib had skin toxicity compared to 7 of the 23 patients treated with gefitinib. Grade 3--4 skin toxicity was observed in five patients among erlotinib arm compared to only one patient among gefitinib arm. Of the nine patients who developed skin rash with erlotinib, four required dose reduction from 150 mg to 100 mg. In four patients, erlotinib was changed to gefitinib, as reducing the dose did not result in decrease in skin toxicities \[[Figure 1](#F1){ref-type="fig"}\]. Gefitinib-induced drug rash was managed conservatively with antihistamines and clindamycin skin ointment without treatment interruption.

![Erlotinib-induced pustular skin lesions affecting face, leg, and hand](IJMPO-38-15-g002){#F1}

Other side effects such as diarrhea and deranged liver function were comparable in both the groups as shown in [Table 2](#T2){ref-type="table"}.

###### 

Toxicity profile of patients treated with TKI\'s
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Discussion {#sec1-4}
==========

Randomized studies have clearly shown survival benefit of TKIs compared to chemotherapy when treating EGFR mutated lung cancer.\[[@ref1][@ref2][@ref3][@ref4]\] TKIs such as erlotinib and gefitinib used in the treatment of EGFR mutated lung cancer have similar toxicity profiles, but the grades and severity of the toxicities have not been studied extensively. In this prospective study, we compared toxicity profile of erlotinib and gefitinib in Indian patients.

In our study, skin toxicity was the most important side effect with erlotinib compared to gefitinib. Nine of the 11 patients treated with erlotinib had skin toxicity with five of them having Grade 3--4 skin rash (45.45%) whereas only 7 of the 23 patients treated with gefitinib had skin toxicity and only one among them had Grade 3--4 skin rash. Grade 3--4 toxicity due to erlotinib in our study was much higher than that found in OPTIMAL and EURTAC studies (2% and 13%, respectively).\[[@ref3][@ref4]\] This probably is because the steady-state plasma trough concentration by erlotinib at its maximal tolerated dose of 150 mg was 3.5 times higher than that produced by gefitinib at its approved dose of 250 mg once daily which was approximately one-third of the maximum tolerated dose.\[[@ref8][@ref9]\]

Because of the skin toxicity, erlotinib dose was reduced to 100 mg in four patients which they could tolerate, and for the other four patients, erlotinib was changed to gefitinib as their skin toxicity recurred with the same severity even following dose reduction. All these four patients tolerated gefitinib well and three of them had Grade 1 rash. In only one patient, erlotinib was continued at 150 mg after treating skin rash with antihistamines and clindamycin topical ointment. There was a significant delay in the treatment in erlotinib arm due to skin toxicity. Treatment had to be stopped for at least 20 days in six of the patients until the rash subsided.

In the gefitinib arm, there were no treatment delays and Grade 2--3 rash was managed with antihistamines and clindamycin topical ointments.

Other side effects such as diarrhea, deranged liver function test, and hand-foot syndrome were comparable in both arms.

The limitation of our study is small sample size. This study can be taken as a pilot study for planning bigger randomized studies.

Conclusion {#sec1-5}
==========

Skin toxicity is a major side effect with erlotinib among Indian patients which results in significant treatment delay, which in turn may adversely affect the survival of patients with EGFR mutant lung cancer. Dose reduction and changing the drug were helpful in patients who could not tolerate 150 mg of erlotinib. Gefitinib had a much more friendly toxicity profile and was well tolerated among Indian patients.
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